CN105385640A - Lactococcus garviea and application thereof - Google Patents
Lactococcus garviea and application thereof Download PDFInfo
- Publication number
- CN105385640A CN105385640A CN201510969991.9A CN201510969991A CN105385640A CN 105385640 A CN105385640 A CN 105385640A CN 201510969991 A CN201510969991 A CN 201510969991A CN 105385640 A CN105385640 A CN 105385640A
- Authority
- CN
- China
- Prior art keywords
- hyperuricemia
- food
- lactococcus
- lactococcus garvieae
- lactococcusgarviea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000194036 Lactococcus Species 0.000 title abstract 7
- 201000001431 Hyperuricemia Diseases 0.000 claims abstract description 31
- 235000013305 food Nutrition 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 21
- 241000194040 Lactococcus garvieae Species 0.000 claims description 43
- 239000008267 milk Substances 0.000 claims description 11
- 235000013336 milk Nutrition 0.000 claims description 11
- 210000004080 milk Anatomy 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 235000013339 cereals Nutrition 0.000 claims description 4
- -1 granular preparation Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 3
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 description 33
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 17
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 17
- 229940116269 uric acid Drugs 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 16
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000006041 probiotic Substances 0.000 description 8
- 235000018291 probiotics Nutrition 0.000 description 8
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 7
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 230000000529 probiotic effect Effects 0.000 description 5
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 4
- 229960002529 benzbromarone Drugs 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 108010046845 tryptones Proteins 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses lactococcus garviea. The collection number of the lactococcus garviea is CCTCC M2015633. The invention further discloses an application of the lactococcus garviea to preparing a medicine or a food for preventing hyperuricemia, and further provides the hyperuricemia-preventing medicine or the hyperuricemia-preventing food with the lactococcus garviea. Experiments prove that the lactococcus garviea is safe, nontoxic and high in pharmacologic effect, and has a quite good treating effect on hyperuricemia, it is indicated that the lactococcus garviea has quite good edible and medicinal prospects accordingly, and a good health-caring and preventing product suitable for hyperuricemia patients is provided in clinic.
Description
Technical field
The invention belongs to microbial technology field, relate to a kind of new Lactococcus garvieae and application thereof.
Background technology
Hyperuricemia (HUA) refers under normal purine diet state, and non-twice fasting blood uric acid level male sex is higher than 420 μm of ol/L on the same day, and women, higher than 360 μm of ol/L, is namely called hyperuricemia.
Hyperuricemia patients is except bringing out because crystallization uric acid deposits to soft tissue, joint, cause acute or chronic disease in cartilage and kidney, and be attended by outside the ventilation of severe pain, also probably develop into ephrosis, urinary stone, cardiovascular disorder, cerebrovascular disorder.In addition, hyperuricemia is considered to cause arteriosclerotic Hazard Factor.
And the drug main of uric acid resisting will divide two kinds at present, a kind of is the Zyloric suppressing uric acid synthesis, and a kind of is the benzbromarone promoting uric acid excretion.The treatment of acute gout is mainly based on the medicine of anti-inflammatory, but these medicines all need health to decompose and discharge, and have certain side effect to liver and kidney.Tiny ecosystem direction treatment hyperuricemia, it is a new development in gout treatment history, it is intended to, with the probiotic bacterium (Probiotics) with specific physiologically active through screening, make various probiotics, realize its physiological action after people takes.Probiotic bacterium, then refer to by improving intestinal microbial balance thus host being applied to the microorganism additive of beneficial effect.
At present, Lactococcus garvieae, as a kind of probiotic bacterium, has been reported to have and has been improved the effect such as immunizing power, optimization intestinal microflora; Can it produce Cucumber and decompose purine in enteron aisle, thus increase purine decomposition and reduce uric acid in serum composition, not yet has the Lactococcus garvieae reported and screen and have this application at present.
Summary of the invention
The object of the present invention is to provide a kind of new Lactococcus garvieae and application thereof.
The technical scheme realizing above-mentioned purpose is as follows.
A kind of Lactococcus garvieae (Lactococcusgarviea), its deposit number is CCTCCM2015633.
Above-mentioned Lactococcus garvieae (Lactococcusgarviea) is preparing the application prevented and treated in the medicine of hyperuricemia.
Or above-mentioned Lactococcus garvieae (Lactococcusgarviea) prevents and treats application in the food of hyperuricemia in preparation.
Wherein in an embodiment, described food is any one in milk powder, milk base leavened food (such as cheese, curdled milk, yoghourt, ice cream etc.), fermented cereal food.
Another object of the present invention is to provide a kind of medicine or the food of preventing and treating hyperuricemia.
Concrete technical scheme is as follows.
Prevent and treat a medicine for hyperuricemia, its activeconstituents includes above-mentioned Lactococcus garvieae (Lactococcusgarviea).
Wherein in an embodiment, the formulation of described medicine is pill, tablet, granular preparation, capsule, oral liquid or tube feed preparation.
Wherein in an embodiment, the amount containing Lactococcus garvieae (Lactococcusgarviea) in described medicine is 10
5~ 10
12cfu/ml or 10
5~ 10
12cfu/g, is more preferably 10
6~ 10
8cfu/ml or 10
6~ 10
8cfu/g.
Prevent and treat a food for hyperuricemia, it includes above-mentioned Lactococcus garvieae (Lactococcusgarviea).
Wherein in an embodiment, described food is any one in milk powder, cheese, curdled milk, yoghourt, ice cream, milk base leavened food, fermented cereal food.
Wherein in an embodiment, the amount containing Lactococcus garvieae (Lactococcusgarviea) in described food is 10
5~ 10
12cfu/ml or 10
5~ 10
12cfu/g, is more preferably 10
6~ 10
8cfu/ml or 10
6~ 10
8cfu/g.
The Lactococcus garvieae (Lactococcusgarviea) that the present invention screens is preserved in Wuhan University's preservation center China typical culture collection center (CCTCC on October 22nd, 2015, address: Luo Jia Shan, wuchang, wuhan), preservation period is 30 years, deposit number CCTCCM2015633.
The present invention has found its new purposes from a kind of Lactococcus garvieae screened, and has opened up the Application Areas that a Lactococcus garvieae is new.The present invention proves by experiment, this strain Lactococcus garvieae safety non-toxic screened, and pharmacological action is strong, has a good therapeutic effect for hyperuricemia, thus has well edible and prospect in medicine predictive of this strain Lactococcus garvieae.Lactococcus garvieae of the present invention is as a kind of probiotics, and can be used for food or the pharmaceutical composition of preparing treatment hyperuricemia, cost is low, effective.
Accompanying drawing explanation
Fig. 1 is the colonial morphology figure of Lactococcus garvieae (Lactococcusgarviea).
Embodiment
Be described in further details the present invention below by embodiment, these embodiments are only used for the present invention is described, do not limit the scope of the invention.
Experimental technique in following embodiment, if no special instructions, is ordinary method.Test materials used in following embodiment, if no special instructions, is and purchases available from routine biochemistry reagent shop.
The separation and purification of embodiment 1 Lactococcus garvieae (Lactococcusgarviea) bacterium liquid
0 is taken by " normal microflora test procedure ".5ml milk fermentation liquid, is placed in the test tube that 4.5ml physiological saline is first housed, and becomes 10 with this serial dilution
-1~ 10
-6, dripped on suitable culture medium flat board to low extent of dilution by high dilution, put in 37 DEG C of constant incubators, microscopy after 2 ~ 7 days.Choose single bacterium colony and carry out pure culture, dyeing microscopic examination, cultural characters, Physiology and biochemistry detection: find the carbohydrate such as this bacterium energy decomposition glucose, lactose, seminose, rhamnosyl, Vitamin C2, synanthrin, produce acid not aerogenesis; The organic acid produced is mainly lactic acid and acetic acid; Decompose Tryptones ability general.The strain that Species estimation through strain bacterium belongs to Lactococcus garvieae (Lactococcusgarviea) is the probiotic bacterium of human body.
This Lactococcus garvieae (Lactococcusgarviea) is with the antagonistic effect of intestinal bacteria, streptococcus aureus, subtilis, Salmonellas etc., find to there is its growth that can suppress above Gram-negative and positive bacteria antagonistic action.
The Species estimation of this strain bacterium belongs to a strain of Lactococcus garvieae (Lactococcusgarviea) without toadstool, is the probiotic bacterium of human body.Be deposited in Wuhan University's preservation center China typical culture collection center (CCTCC), preservation date on October 22nd, 2015, deposit number CCTCCM2015633.
Microscopic examination, the as shown in Figure 1 colonial morphology of Lactococcus garvieae (Lactococcusgarviea).
On Bd culture medium flat plate, colonial morphology is medium sized circle, smooth, canescence, protuberance, translucent.Gram's staining is negative, shaft-like, single or arrange in pairs, and two terminal circle is blunt.
In addition, above-mentioned Lactococcus garvieae strain has been deposited in Wuhan University's preservation center China typical culture collection center (CCTCC), preservation date on October 22nd, 2015, deposit number CCTCCM2015633.
In following examples, used Lactococcus garvieae for deposit number be the Lactococcus garvieae of CCTCCM2015633.
Embodiment 2
The Zengjing Granule of Lactococcus garvieae (Lactococcusgarviea) and bacterium solution preparation
Choose the single colony inoculation of Lactococcus garvieae described in the embodiment after purifying 1 and carry out Zengjing Granule in the Tryptones meat soup improved, the centrifugation of gained bacterium liquid, rotating speed 3000r/min, centrifugal 15min, remove supernatant, after throw out brine, throw out normal saline dilution, do Counting alive microbial with Maxwell opacity tube, be diluted to 10
6cfu/ml, 10
7cfu/ml, 10
8cfu/ml, saves backup.
Experimentation on animals
(1) Lactococcus garvieae is on the impact of mice serum uric acid level
Modeling is after 14 days, and the uric acid level of model group, apparently higher than blank group (P<0.01), shows modeling success.Successive administration is after 7 days, and mice serum uric acid level obvious reduction compared with model group of positive control drug benzbromarone tablets 16.7mg/kg group, has statistical significance (P<0.01); Three dosage group (bacterium numbers 10 of tested medicine
6cfu/ml group, bacterium number 10
7cfu/ml group, bacterium number 10
8cfu/ml group) compared with model group, can obviously reduce mice serum uric acid level, and dosage and uric acid are in negative straight line correlation (P<0.01), in table 1.
Table 1 viable bacteria is on the impact of hyperuricemia mice serum uric acid level
Note: (n=10, x ± s.d); Compared with blank group ,=P<0.01; Compared with model group, * * P<0.01.
(2) Lactococcus garvieae is on the impact of Mouse Blood blood urea nitrogen
Successive administration is after 7 days, and Mouse Blood urea nitrogen levels obvious reduction compared with model group of positive control drug benzbromarone tablets 16.7mg/kg group, has statistical significance (P<0.01); Three dosage group (bacterium numbers 10 of tested medicine
6cfu/ml group, bacterium number 10
7cfu/ml group, bacterium number 10
8cfu/ml group) compared with model group, can obviously reduce Mouse Blood urea nitrogen levels, and dosage and uric acid are in negative straight line correlation (P<0.01), in table 2
Table 2 viable bacteria is on the impact of hyperuricemia Mouse Blood urea nitrogen levels
Note: (n=10, x ± s.d); Compared with blank group ,=P<0.01; Compared with model group, * * P<0.01.
(3) on the impact of mice serum NO
High dosage (the bacterium number 10 of successive administration benzbromarone tablets 16.7mg/kg group and Lactococcus garvieae viable bacteria after 7 days
8cfu/ml) organize NO level obviously to increase, there is significant difference (P<0.01 and P<0.05) compared with model group, in table 3.
Table 3 viable bacteria is on the impact of hyperuricemia mice serum NO level
Note: (n=10, x ± s.d); Compared with model group: * P<0.05, * * P<0.01.
(4) on the impact of mice serum creatinine, blood urea nitrogen
Mouse successive administration after 7 days model group and 5 administration group serum creatinines and blood urea nitrogen all close to normal level, show that modeling has no significant effect, in table 4 with administration 7 days serum creatinines to hyperuricemia mouse, blood urea nitrogens for 14 days.
Table 4 viable bacteria is on the impact of hyperuricemia mice serum creatinine, uric acid level
Note: n=10, x ± s.d
Conclusion
The hyperuricemia that application male mice in kunming causes, can maintain higher serum uric acid level within the observation period, for the curative effect evaluating the anti-hyperuricemia of medicine provides reliable model.Hyperuricemia Mouse oral viable bacteria bacterium number 10 after 7 days
7cfu/ml and bacterium number 10
8cfu/ml dosage group demonstrates the effect significantly reducing serum uric acid, increasing serum NO.The rising of NO level, may improve the blood vessel endothelium injury because Serum Uric Acid causes to a certain extent.The administration of hyperuricemia Mouse oral had no significant effect serum creatinine, blood urea nitrogen index in 7 days.
Microbial culture is tested
Bacterium number is 10
6the Lactococcus garvieae of cfu/ml and milk-acid bacteria measure the purine concentration in substratum, in table 5 after cultivating in 10mmol/L height purine substratum respectively in 24 hours.As shown in Table 5, during the 24h of Lactococcus garvieae, in substratum, purine concentration drops to 0.8mmol/L from 10mmol/l, presents extremely strong Decomposition.
Table 5 Lactococcus garvieae is to the Decomposition of high purine substratum
Embodiment 3 is made into tablet and powder
(1) preparation of viable bacteria tablet
The dosage that viable bacteria tablet is raw materials used and compacting 1000 is used prepared by table 6
Remarks: in every g, Lactococcus garvieae is all greater than 10
6cfu.
Preparation technology: by the pulverizing of bacterium powder, Microcrystalline Cellulose, polyvinylpolypyrrolidone and the Magnesium Stearate ,-proportioning materials that sieves, mixing-wet granulation-particle drying-compressing tablet (if desired dressing)-tablet quality inspection-pack and get final product.
Tablet quality inspection should be noted:
A. outward appearance should be complete bright and clean, and uniform color, has suitable hardness, in order to avoid there is fragment in packaging storing;
B. tablet weight variation: tablet taking 20, accurately weighed gross weight, after trying to achieve average sheet weight, distinguish the weight of accurately weighed each again, every sheet weight compares with average sheet heavy phase, and the tablet exceeding limit test of weight variation more than 2, and must not must not have one times of 1 overrun.
Each technical characteristic of the above embodiment can combine arbitrarily, for making description succinct, the all possible combination of each technical characteristic in above-described embodiment is not all described, but, as long as the combination of these technical characteristics does not exist contradiction, be all considered to be the scope that this specification sheets is recorded.
The above embodiment only have expressed several embodiment of the present invention, and it describes comparatively concrete and detailed, but can not therefore be construed as limiting the scope of the patent.It should be pointed out that for the person of ordinary skill of the art, without departing from the inventive concept of the premise, can also make some distortion and improvement, these all belong to protection scope of the present invention.Therefore, the protection domain of patent of the present invention should be as the criterion with claims.
Claims (10)
1. a Lactococcus garvieae (Lactococcusgarviea), its deposit number is CCTCCM2015633.
2. Lactococcus garvieae according to claim 1 (Lactococcusgarviea) is preparing the application prevented and treated in the medicine of hyperuricemia.
3. Lactococcus garvieae according to claim 1 (Lactococcusgarviea) is preparing the application prevented and treated in the food of hyperuricemia.
4. application according to claim 3, is characterized in that, described food is any one in milk powder, milk base leavened food, fermented cereal food.
5. prevent and treat a medicine for hyperuricemia, it is characterized in that, its activeconstituents includes Lactococcus garvieae according to claim 1 (Lactococcusgarviea).
6. medicine according to claim 5, is characterized in that, the formulation of described medicine is pill, tablet, granular preparation, capsule, oral liquid or tube feed preparation.
7. the medicine according to claim 6 or 7, is characterized in that, the amount of described Lactococcus garvieae (Lactococcusgarviea) is 10
5~ 10
12cfu/ml or 10
5~ 10
12cfu/g.
8. prevent and treat a food for hyperuricemia, it is characterized in that, it includes Lactococcus garvieae according to claim 1 (Lactococcusgarviea).
9. food according to claim 8, is characterized in that, described food is any one in milk powder, milk base leavened food, fermented cereal food.
10. food according to claim 8 or claim 9, it is characterized in that, the amount of the described Lactococcus garvieae (Lactococcusgarviea) in described food is 10
5~ 10
12cfu/ml or 10
5~ 10
12cfu/g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510969991.9A CN105385640B (en) | 2015-12-18 | 2015-12-18 | Lactococcus garvieae and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510969991.9A CN105385640B (en) | 2015-12-18 | 2015-12-18 | Lactococcus garvieae and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105385640A true CN105385640A (en) | 2016-03-09 |
| CN105385640B CN105385640B (en) | 2018-07-27 |
Family
ID=55418425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510969991.9A Active CN105385640B (en) | 2015-12-18 | 2015-12-18 | Lactococcus garvieae and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105385640B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105861400A (en) * | 2016-06-17 | 2016-08-17 | 江苏省农业科学院 | Lactococcus garviea, biological preservative and applications of lactococcus garviea and biological preservative |
| CN110373365A (en) * | 2019-08-27 | 2019-10-25 | 岭南师范学院 | One plant of Lactococcus Lactococcus garvieae LGHK2 and its application |
| CN111363706A (en) * | 2020-04-13 | 2020-07-03 | 天津中医药大学 | Ecliptae herba endophytic bacteria, eclipta alba composition and application thereof |
| CN113980853A (en) * | 2021-11-12 | 2022-01-28 | 河南省科学院生物研究所有限责任公司 | Lactococcus garvieae WBT0008 capable of producing lactic acid at high yield and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004112809A1 (en) * | 2003-06-24 | 2004-12-29 | Otsuka Pharmaceutical Co., Ltd. | Composition for lowering serum uric acid level |
| CN102016004A (en) * | 2007-11-30 | 2011-04-13 | 明治乳业株式会社 | Lactic acid bacterium having effect of lowering blood uric acid level |
-
2015
- 2015-12-18 CN CN201510969991.9A patent/CN105385640B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004112809A1 (en) * | 2003-06-24 | 2004-12-29 | Otsuka Pharmaceutical Co., Ltd. | Composition for lowering serum uric acid level |
| CN102016004A (en) * | 2007-11-30 | 2011-04-13 | 明治乳业株式会社 | Lactic acid bacterium having effect of lowering blood uric acid level |
Non-Patent Citations (3)
| Title |
|---|
| JIAN-TONG LI等: "Dopamine depresses the immune ability and increases susceptibility to Lactococcus garvieae in the freshwater giant prawn, Macrobrachium rosenbergii", 《FISH & SHELLFISH IMMUNOLOGY》 * |
| 曲以之等: "痛风及微生态防治的相关进展", 《中国微生态学杂志》 * |
| 杨殿斌等: "降血尿酸乳酸菌筛选及其对高尿酸血症模型大鼠作用研究", 《中国微生态学杂志》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105861400A (en) * | 2016-06-17 | 2016-08-17 | 江苏省农业科学院 | Lactococcus garviea, biological preservative and applications of lactococcus garviea and biological preservative |
| CN110373365A (en) * | 2019-08-27 | 2019-10-25 | 岭南师范学院 | One plant of Lactococcus Lactococcus garvieae LGHK2 and its application |
| CN110373365B (en) * | 2019-08-27 | 2021-03-02 | 岭南师范学院 | Lactobacillus garvieae LGHK2 and application thereof |
| CN111363706A (en) * | 2020-04-13 | 2020-07-03 | 天津中医药大学 | Ecliptae herba endophytic bacteria, eclipta alba composition and application thereof |
| CN113980853A (en) * | 2021-11-12 | 2022-01-28 | 河南省科学院生物研究所有限责任公司 | Lactococcus garvieae WBT0008 capable of producing lactic acid at high yield and application thereof |
| CN113980853B (en) * | 2021-11-12 | 2023-05-26 | 河南省科学院生物研究所有限责任公司 | Lactic acid-producing lactococcus garvieae WBT0008 and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105385640B (en) | 2018-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9394513B2 (en) | Method for fermentation and cultivation, fermented plant extract, fermented plant extract powder, and composition containing the extract of fermented plant | |
| JP5498698B2 (en) | New uses of white jellyfish miscellaneous polysaccharides or their extracts | |
| CN110157649A (en) | It is a kind of to have effects that improve the lactobacillus paracasei L9 of people's constipation and its application | |
| CN105385640A (en) | Lactococcus garviea and application thereof | |
| CN112999261A (en) | Natto fermented composition capable of relieving arteriosclerosis and preparation method and application thereof | |
| CN114574406B (en) | Lactobacillus rhamnosus strain WKA55, and application and product thereof in preparation of product for preventing and treating alcoholic liver injury | |
| CN107692219A (en) | A kind of hypoglycemic fruit zymotic fluid and preparation method thereof | |
| CN102618452B (en) | Preparation method, composition and application of lactobacillus salivarius and its metabolites | |
| CN104415061A (en) | Edible composition as well as preparation method and application thereof | |
| CN113249280A (en) | Streptococcus thermophilus STN26, bacterium powder and application in uric acid reducing product | |
| CN103948023B (en) | The health food of a kind of develop immunitypty and improving water flood and two-step fermentation preparation method thereof | |
| CN105535580A (en) | A biological agent for improving human body intestinal floras and a preparing method thereof | |
| CN104799286A (en) | Composition for improving immunity and preparation method of composition | |
| CN104719914B (en) | A kind of composition for improving gastrointestinal function and preparation method thereof | |
| CN103355675B (en) | Composition with lung clearing function and preparation method | |
| CN107375466A (en) | A kind of medicine-food two-purpose zymotic fluid with hypolipemic function and preparation method thereof | |
| CN107048408A (en) | Prepare improves cancer patient illness, the fermentation composition of the plant enzyme of raising life quality effect and preparation method with conditioning | |
| CN106036852A (en) | Method for preparing probiotic fermented functional healthcare food with arctium lappa | |
| CN116286537B (en) | Lactobacillus paracasei GF045 with auxiliary weight-losing effect and application thereof | |
| CN104013650B (en) | Bacillus licheniformis and herbal polysaccharide composition and its preparation | |
| CN118059188B (en) | Bifidobacterium longum SF-B-60 metazoan bacterial agent and preparation method and application thereof | |
| CN109320625B (en) | Extraction method and application of angelica sinensis polysaccharide | |
| CN111528478A (en) | Compound beneficial microbial preparation for treating constipation and preparation method thereof | |
| CN116287008A (en) | Peptide, peptide capsule and application thereof in aspects of medicines for treating colonitis | |
| CN108741088A (en) | Heat-resisting probiotic composition and health food comprising the composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |